Premium
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia
Author(s) -
Inaba Hiroto,
Stewart Clinton F.,
Crews Kristine R.,
Yang Shengping,
Pounds Stanley,
Pui ChingHon,
Rubnitz Jeffrey E.,
Razzouk Bassem I.,
Ribeiro Raul C.
Publication year - 2009
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.24712
Subject(s) - medicine , cladribine , topotecan , refractory (planetary science) , hematopoietic stem cell transplantation , cytarabine , myeloid leukemia , gastroenterology , regimen , transplantation , neutropenia , chemotherapy , oncology , surgery , physics , astrobiology
BACKGROUND: The prognosis after recurrence of pediatric acute myeloid leukemia (AML) is poor, and effective salvage regimens are urgently needed. METHODS: In phase 1 and pilot studies, the authors evaluated the maximum tolerated dose (MTD) and dose‐limiting toxicities (DLTs) of a 5‐day course of cladribine followed by topotecan in pediatric patients with recurrent/refractory AML. The cladribine dose was escalated as follows: 9.1, 13.6, 16.3, and 19.5 mg/m 2 per day (8.9 mg/m 2 per day in the pilot study). Outcome was analyzed according to the absence (Stratum 1) versus presence (Stratum 2) of previous allogeneic hematopoietic stem cell transplantation. Twenty‐six patients (20 in Stratum 1 and 6 in Stratum 2) were treated. RESULTS: The MTD was not reached in Stratum 1, but a DLT occurred at the lowest cladribine dosage (9.1 mg/m 2 per day) in Stratum 2. Febrile neutropenia was common in both strata. Nine (34.6%) of 26 patients experienced a complete response, and 7 (30.4%) achieved a partial response; 5 (19.2%) were long‐term survivors at the time of last follow‒up. Clinical outcome was not associated with cladribine or topotecan systemic exposure. CONCLUSIONS: The combination was well tolerated in Sratum 1, and the response rate was encouraging. This regimen offers a postrecurrence treatment alternative for patients, especially those who have received anthracycline‐containing chemotherapy. Cancer 2010. © 2010 American Cancer Society.